Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

Maaike A.C. Bruin, Gabe S. Sonke, Jos H. Beijnen, Alwin D.R. Huitema

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)

Abstract

Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer. Poly (ADP-ribose) polymerase inhibitors are potent inhibitors of the PARP enzymes with comparable half-maximal inhibitory concentrations in the nanomolar range. Olaparib and rucaparib are orally dosed twice a day, extensively metabolized by cytochrome P450 enzymes, and inhibitors of several enzymes and drug transporters with a high risk for drug–drug interactions. Niraparib and talazoparib are orally dosed once a day with a lower risk for niraparib and a minimal risk for talazoparib to cause drug–drug interactions. All four PARP inhibitors show moderate-to-high interindividual variability in plasma exposure. Higher exposure is associated with an increase in toxicity, mostly hematological toxicity. For talazoparib, exposure–efficacy relationships have been described, but for olaparib, niraparib, and rucaparib this relationship remains inconclusive. Further studies are required to investigate exposure–response relationships to improve dosing of PARP inhibitors, in which therapeutic drug monitoring could play an important role. In this review, we give an overview of the pharmacokinetic properties of the four PARP inhibitors, including considerations for patients with renal dysfunction or hepatic impairment, the effect of food, and drug–drug interactions. Furthermore, we focus on the pharmacodynamics and summarize the available exposure–efficacy and exposure–toxicity relationships.

Original languageEnglish
Pages (from-to)1649-1675
Number of pages27
JournalClinical Pharmacokinetics
Volume61
Issue number12
DOIs
Publication statusPublished - Dec 2022

Fingerprint

Dive into the research topics of 'Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology'. Together they form a unique fingerprint.

Cite this